生发中心
BCL6公司
弥漫性大B细胞淋巴瘤
增强子
B细胞
淋巴瘤
体细胞突变
染色质
乘客5人
癌症研究
生物
转录因子
遗传学
基因
免疫学
抗体
作者
Ashwin Iyer,Aishwarya Gurumurthy,Alec Chu,Rohan Kodgule,Athalee R. Aguilar,Travis Saari,Abdullah Ramzan,Jan Rosa,Juhi Gupta,Arvind Emmanuel,Cody N. Hall,John S. Runge,Anna B. Owczarczyk,Jang Hwan Cho,Matthew B. Weiss,Rockwell Anyoha,Kristin Sikkink,Savanna Gemus,Charles P. Fulco,Anamarija M. Perry
标识
DOI:10.1158/2643-3230.bcd-24-0126
摘要
Abstract High expression of MYC and its target genes identify germinal center B-cell diffuse large B-cell lymphomas (GCB-DLBCL) associated with poor outcomes. We used CRISPR-interference profiling of human lymphoma cell lines to define essential enhancers in the MYC locus and non-immunoglobulin rearrangement partner loci, including a recurrent rearrangement between MYC and the BCL6 locus control region. GCB-DLBCL cell lines without MYC rearrangement are dependent on an evolutionarily-conserved enhancer we name “germinal center MYC enhancer 1” (GME-1), which is activated by the transcription factor complex of OCT2, OCA-B, and MEF2B, shows an active chromatin state in normal human and mouse germinal center B cells, and demonstrates selective acetylation and MYC promoter topological interactions in MYC-intact GCB-DLBCL biopsies. Whole-genome sequencing identified tandem copy gains of the GME-1 enhancer as a rare but recurrent event in DLBCL. Our findings shed new light on mechanisms that dysregulate MYC, a key driver of B cell malignancy.
科研通智能强力驱动
Strongly Powered by AbleSci AI